Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 146″]

Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?

Want to know more about these podcast guests?

Vicken Karageozian, MD: https://ois.net/vicken-karageozian/